| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
| ln Vitro |
In MDA-MB-231 cells, ziyugluside I (5-160 µM; 24 hours) exhibits strong anti-proliferative action, with an IC50 value of 13.96 µM [2]. Ziyugluside I (5–20 µM; 24 hours) increases the proportion of apoptotic cells from 2.43% to 44.76% (20 µM) in MDA-MB-231 cells, hence inducing apoptosis [2]. Induction of caspase-8, caspase-9, and caspase-3 cleavage, upregulation of the pro-apoptotic protein Bax, downregulation of the anti-apoptotic protein Bal-2, and dose-dependent reduction of mitochondrial cell c expression level are all caused by ziyugluside I (5–20 µM; 24-hour exposure)[2].
|
|---|---|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: MDA-MB-231 Cell Tested Concentrations: 5 µM, 10 µM, 20 µM, 40 µM, 80 µM and 160 µM Incubation Duration: 24 hrs (hours) Experimental Results: MDA-MB-231 shows cytotoxic cells . Cell cycle analysis[1] Cell Types: MDA-MB-231 Cell Tested Concentrations: 5 µM, 10 µM and 20 µM Incubation Duration: 24 hrs (hours) Experimental Results: Induction of G2/M phase arrest and apoptosis in MDA-MB-231 cells Western Blot analysis [1] Cell Types: MDA-MB-231 Cell Tested Concentrations: 5 µM, 10 µM and 20 µM Incubation Duration: 24 hrs (hours) Experimental Results: Induction of apoptosis in MDA-MB-231 cells via intrinsic and extrinsic pathways. |
| References |
|
| Additional Infomation |
Ziyuglycoside I has been reported in Rubus ellipticus var. obcordatus, Ilex paraguariensis, and other organisms with data available.
|
| Molecular Formula |
C41H66O13
|
|---|---|
| Molecular Weight |
766.95494
|
| Exact Mass |
766.45
|
| CAS # |
35286-58-9
|
| PubChem CID |
71609288
|
| Appearance |
White to off-white solid powder
|
| Density |
1.35
|
| Boiling Point |
841.9±65.0 °C at 760 mmHg
|
| Melting Point |
198-202ºC
|
| Flash Point |
247.2±27.8 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.610
|
| LogP |
6.59
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
54
|
| Complexity |
1470
|
| Defined Atom Stereocenter Count |
19
|
| SMILES |
C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)O[C@H]6[C@@H]([C@H]([C@H](CO6)O)O)O)C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O
|
| InChi Key |
WCHBFWOEFOZHMK-MLHVESHNSA-N
|
| InChi Code |
InChI=1S/C41H66O13/c1-20-10-15-41(35(49)54-34-31(48)29(46)28(45)23(18-42)52-34)17-16-38(5)21(32(41)40(20,7)50)8-9-25-37(4)13-12-26(36(2,3)24(37)11-14-39(25,38)6)53-33-30(47)27(44)22(43)19-51-33/h8,20,22-34,42-48,50H,9-19H2,1-7H3/t20-,22+,23-,24+,25-,26+,27+,28-,29+,30-,31-,32-,33+,34+,37+,38-,39-,40-,41+/m1/s1
|
| Chemical Name |
[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (1R,2R,4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-1-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-10-[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxy-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
MEthanol : ~125 mg/mL (~162.98 mM)
DMSO : ~100 mg/mL (~130.38 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (2.71 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (2.71 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (2.71 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3038 mL | 6.5192 mL | 13.0385 mL | |
| 5 mM | 0.2608 mL | 1.3038 mL | 2.6077 mL | |
| 10 mM | 0.1304 mL | 0.6519 mL | 1.3038 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
